On Constant Currency Basis (CER), U.S. sales up +17% Y/Y in H1 and +23% in Q2 Record U.S. sales productivity despite ongoing safeguard...
Mauna Kea Technologies Reports First Half 2025 Revenue
read more
Search Results
Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership
Leveraging strong momentum for the CellTolerance® application, Mauna Kea Technologies is expanding into new geographies with high growth...
Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S.
14th U.S. AI patent awarded complementing a comprehensive portfolio of AI-related intellectual property An ecosystem built around the...
Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio
Clinical team at Stanford Health Care achieved the CellTolerance 100-case milestone with the Cellvizio® platform in less than 6 months The...
Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure
Bridge financing through the issuance of convertible bonds to Vester Finance and European investors for €1.8m Immediate receipt of the entire...
Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure
Structuring of financing in progress to secure the safeguard period and support long-term development plan Authorization to implement the...
Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025
All the resolutions proposed by the Board of Directors were adopted Paris and Boston, June 5, 2025 - 5:45 p.m. CEST - Mauna Kea Technologies...
Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification
Cellvizio® technology combined with AI outperforms human experts in pancreatic cyst risk stratification, a major breakthrough for patient...
Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress
Ongoing Strategic Negotiations Towards a Licensing Agreement Strong Momentum for CellTolerance: Over 1,500 Procedures Completed, New Centers...
Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation
Paris and Boston, May 20, 2025 - 5:45 p.m. CEST - Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025
Over 75 physicians attended educational presentations about the breakthrough impact of needle-based Confocal Laser Endomicroscopy and AI on the...
Publication of the 2024 Annual Financial Report
Paris and Boston, April 30, 2025 – 9:15 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...